FOXA1: A promising prognostic marker in breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 11-16

  Hu, Qing ^a   Luo, Zhou ^b   Xu, Tao ^b   Zhang, Jun Ying ^a   Zhu, Ying ^b   Chen, Wei Xian ^b   Zhong, Shan Liang ^c   Zhao, Jian Hua ^c   Tang, Jin Hai ^c  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c JIANGSU CANCER HOSPITAL   (China)

Author keywords

Biomarker; Breast cancer; FOXA1; Prognosis; Systematic review

Indexed keywords

FOXA1 PROTEIN, HUMAN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TUMOR MARKER;

BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; METABOLISM; PHYSIOLOGY; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894042064     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.11     Document Type: Review

References (30)

1. Ademuyiwa FO, Thorat MA, Jain RK, et al (2010). Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol, 23, 270-5.
2. Albergaria A, Paredes J, Sousa B, et al (2009). Expression of FOXA1 and GATA-3 in breast cancer: the prognostic signifificance in hormone receptor-negative tumours. Breast Cancer Res, 11, R40.
3. Badve S, Nakshatri H (2009). Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classififications. J Clin Pathol, 62, 6-12.
4. Badve S, Turbin D, Thorat MA, et al (2007). FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res, 13, 4415-21.
5. Beck S, Sommer P, dos Santos Silva E, et al (1999). Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box. DNA Cell Biol, 18, 157-64.
6. Bernardo GM, Keri RA (2012). FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep, 32, 113-30.
7. Bernardo GM, Lozada KL, Miedler JD, et al (2010). FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development, 137, 2045-54.
8. Carroll JS, Brown M (2006). Estrogen receptor target gene: an evolving concept. Mol Endocrinol, 20, 1707-14.
9. Costa RH, Grayson DR, Darnell JE, et al (1989). Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol, 9, 1415-25.
10. Desantis C, Ma J, Bryan L, et al (2013). Breast cancer statistics. CA Cancer J Clin, 9, 69-90.
11. Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
12. Habashy HO, Powe DG, Rakha EA, et al (2008). Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic signifificance. Eur J Cancer, 44,1541-51.
13. Hayes DF (2005). Prognostic and predictive factors revisited. Breast, 14, 493-9.
14. Hisamatsu Y, Tokunaga E, Yamashita N, et al (2012). Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol, 19, 1145-52.
15. Hurtado A, Holmes KA, Ross-Innes CS, et al (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet, 43, 27-33.
16. Ijichi N, Shigekawa T, Ikeda K, et al (2012). Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer, 3, 147-59.
17. Kawase M, Toyama T, Takahashi S, et al (2013). FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. [Epub ahead of print]
18. Kim C, Paik S 2010. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol, 7, 340-7.
19. Knight WA, Osborne CK, Yochmowitz MG, et al (1980). Steroid hormone receptors in the management of human breast cancer. Ann Clin Res, 12, 202-7.
20. Kouros-Mehr H, Slorach EM, Sternlicht MD, et al (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127, 1041-55.
21. Liu N, Niu Y, Wang SL, et al (2010). Diagnostic and prognostic sign ifificance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas. Zhonghua Yi Xue Za Zhi, 90, 1403-7.
22. Mehta RJ, Jain RK, Leung S, et al (2012). FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat, 131, 881-90.
23. Nakshatri H, Badve S (2007). FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets, 11, 507-14.
24. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
25. Sircoulomb F, Bekhouche I, Finetti P, et al (2010). Genome profifiling of ERBB2-amplifified breast cancers. BMC Cancer, 10, 539.
26. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869-10874.
27. Thorat MA, Marchio C, Morimiya A, et al (2007). Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol, 61, 327-32.
28. Wolf I, Bose S, Williamson EA, et al (2007). FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer, 120, 1013-22.
29. Yamaguchi N, Ito E, Azuma S, et al (2008). FoxA1 as a lineage-specifific oncogene in luminal type breast cancer. Biochem Biophys Res Commun, 365, 711-7.
30. Yerushalmi R, Woods R, Ravdin PM, et al (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83.